Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targeting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells.
MDNA11 is an experimental cancer therapy that belongs to a class of medications called cytokine therapies. Cytokines are signalling molecules that are used by the immune system to communicate and promote the destruction of damaged or dangerous cells. MDNA11 is a human-engineered version of the interleukin-2 (IL-2) molecule.
Since this drug is still in the clinical trial phase, it has the placeholder name MDNA11 rather than a commercial trade name.
This is a phase 1/2 study that will investigate the safety and effectiveness of MDNA11 either alone or in combination with Pembrolizumab in patients with several different cancer types, including kidney cancer.
The treatment you receive will be assigned at random by the doctor overseeing your care.
Group 1: MDNA11 alone
Group 2: MDNA11 + Pembrolizumab
There is no control group in the study, so there will be no “placebo”, and all eligible patients will receive treatment.
- Clear cell kidney cancer only
- Advanced kidney cancer that cannot be removed by surgery
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentrePrincess Margaret Cancer Center||Principal InvestigatorNot Given||LocationToronto, ON||Trial StatusRecruiting|